RE:Theralase Announces Settlement AgreementWith these matters resolved and behind us, we can now direct all of our energy towards executing on the Company’s primary business strategy, the development and commercialization of our Anti-Cancer Technology. This strategy commences with the completion and Health Canada approval of our Phase I Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study in 2018, allowing the Company the ability to commence an adaptive, multi-center Phase II
Read more at https://www.stockhouse.com/companies/bullboard?symbol=v.tlt&postid=27623778#2SsRBpO55mfl7c6S.99
Primary business strategy .....sounds good to me . AM knows all about the trial and the science at hand . At this stage of the company a CEO with a PHD at the end of his name makes sense . Like Vestor says ; P7 the doctor will see you now .
Cheers